A number of other research firms have also commented on NEPT. Zacks Investment Research lowered shares of Neptune Wellness Solutions from a “buy” rating to a “hold” rating in a research report on Thursday, July 18th. Echelon Wealth Partners reiterated a “buy” rating on shares of Neptune Wellness Solutions in a research report on Wednesday, July 24th.
NEPT stock opened at $4.67 on Tuesday. The company has a 50 day moving average price of $5.11. Neptune Wellness Solutions has a 12 month low of $2.42 and a 12 month high of $6.57. The company has a market capitalization of $445.61 million, a price-to-earnings ratio of -33.36 and a beta of 1.67.
Neptune Wellness Solutions (NASDAQ:NEPT) (TSE:NTB) last released its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). Neptune Wellness Solutions had a negative net margin of 94.47% and a negative return on equity of 19.34%. The firm had revenue of $3.26 million during the quarter, compared to the consensus estimate of $4.51 million. Analysts anticipate that Neptune Wellness Solutions will post 0.03 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the business. Two Sigma Advisers LP bought a new stake in Neptune Wellness Solutions during the fourth quarter valued at approximately $367,000. Deutsche Bank AG lifted its position in Neptune Wellness Solutions by 245.9% during the fourth quarter. Deutsche Bank AG now owns 517,135 shares of the biotechnology company’s stock valued at $1,313,000 after purchasing an additional 367,614 shares during the last quarter. Alpine Group USVI LLC bought a new stake in Neptune Wellness Solutions during the first quarter valued at approximately $303,000. CIBC World Markets Inc. bought a new stake in Neptune Wellness Solutions during the first quarter valued at approximately $63,000. Finally, Morgan Stanley lifted its position in Neptune Wellness Solutions by 9.1% during the second quarter. Morgan Stanley now owns 208,980 shares of the biotechnology company’s stock valued at $909,000 after purchasing an additional 17,361 shares during the last quarter. Institutional investors and hedge funds own 12.22% of the company’s stock.
Neptune Wellness Solutions Company Profile
Neptune Wellness Solutions Inc, a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils.
Read More: Should You Consider an Index Fund?
Receive News & Ratings for Neptune Wellness Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neptune Wellness Solutions and related companies with MarketBeat.com's FREE daily email newsletter.